GlaxoSmithKline is teaming up with Google’s parent company Alphabet to create a new company focused on developing bioelectronic medicines.
News
Pfizer snaps up gene therapy group Bamboo for $645m
Pfizer has snapped up the remaining stake in privately-held, US gene therapy group Bamboo Therapeutics in a deal that could be worth as much $645 million.
NICE challenges doctors to prevent 8,000 strokes a year
The National Institute for Health and Care Excellence has published new indicators for healthcare professionals that could prevent thousands of people from having a stroke.
Eisai, NHS and NICE fail to reach deal on Lenvima
Patients with an advanced form thyroid cancer may have to wait three years for NHS access to Eiasai’s Lenvima in England, after the drug was left out of the newly launched Cancer Drugs Fund.
Wales endorses NHS use of Celgene’s Revlimid
Around 300 patients with multiple myeloma in Wales will get National Health Service access to treatment with Celgene’s Revlimid after the drug was recommended for first-line use by cost regulators.
US fast track for Shire’s liver drug
US regulators have placed Shire’s SHP626 on a fast-track regulatory pathway in the hope of potentially accelerating access to the experimental liver disease drug.
EU nod for MSD hep C therapy
European regulators have waved through Merck, Sharp & Dohme’s Zepatier bringing a new treatment option to patients with hepatitis C.
NICE denies cystic fibrosis patients access to Orkambi
Patients with cystic fibrosis will not get ‘routine’ access to treatment with Vertex’ Orkambi in England after the drug was ruled too expensive for NHS use.
Controversial CDF revamp launches
England’s Cancer Drugs Fund (CDF) reopens under its new model, but the industry is warning that it could do little to solve fundamental problems with drug reimbursement.
New international AMR partnership launched
The US government has announced a new global partnership to tackle the health threat posed by antimicrobial resistance, involving two UK partners.
GSK bolsters asthma pipeline
GSK has in-licensed a targeted biological therapy for severe asthma from Janssen, strengthening its respiratory pipeline.
Teva divests 79 drugs to clear Allergan deal
Teva’s purchase of Allergan’s generics business has been cleared by US antitrust authorities after the company agreed to divest 79 of its generic drugs.
Investigation claims NHS impeding access to hep-c drugs
An investigation published by The BMJ has claimed that the NHS is ‘rationing’ Gilead’s high priced hepatitis C drugs Sovaldi and Harvoni.
Dynamic and different L&D prospect for Pharma marketers and teams
Enter the prestigious PharmaTimes Marketer of the Year competition, designed to benchmark talent within your organisation and across our industry. The entry deadline is 31 August, so don’t delay!
GSK invests £275m in UK manufacturing
GSK has announced that it will invest £275 million into three of its manufacturing sites in the UK to boost production and support delivery of its respiratory and large molecule biological drugs.
